Published in Neuron on November 01, 1999
Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 8.66
Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol (2006) 4.32
Ageing and neuronal vulnerability. Nat Rev Neurosci (2006) 3.36
Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol (2002) 3.35
Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J (2001) 3.22
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron (2009) 3.15
TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol (2010) 2.81
Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A (2004) 2.48
Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol (2006) 2.47
Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest (2002) 2.47
Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A (2013) 2.27
Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 2.09
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov (2009) 2.08
Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci (2013) 2.05
Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A (2001) 2.00
Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A (2003) 1.90
Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature (2015) 1.85
GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell (2009) 1.84
Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav (2008) 1.80
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol (2009) 1.76
Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol (2009) 1.75
Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation. Hum Mol Genet (2011) 1.72
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med (2011) 1.68
Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol (2006) 1.68
Drosophila models of neurodegenerative diseases. Annu Rev Pathol (2009) 1.67
Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J Neurosci (2008) 1.65
Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci U S A (2008) 1.64
Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem (2008) 1.64
Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci (2010) 1.60
The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci (2012) 1.60
Mapping superoxide dismutase 1 domains of non-native interaction: roles of intra- and intermolecular disulfide bonding in aggregation. J Neurochem (2006) 1.59
Aberrant splicing of tau pre-mRNA caused by intronic mutations associated with the inherited dementia frontotemporal dementia with parkinsonism linked to chromosome 17. Mol Cell Biol (2000) 1.53
Memory performance is related to amyloid and tau pathology in the hippocampus. J Neurol Neurosurg Psychiatry (2009) 1.52
The genetics of axonal transport and axonal transport disorders. PLoS Genet (2006) 1.49
Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci (2008) 1.44
Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J Alzheimers Dis (2008) 1.43
Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells. Mol Biol Cell (2000) 1.39
Modulating the expression of disease genes with RNA-based therapy. PLoS Genet (2007) 1.38
Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J Clin Invest (2008) 1.37
Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Cell (2012) 1.36
The cytoskeleton in neurodegenerative diseases. J Pathol (2004) 1.35
Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation. Am J Pathol (2003) 1.34
Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J (2013) 1.31
Tau isoform regulation is region- and cell-specific in mouse brain. J Comp Neurol (2008) 1.29
Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am J Pathol (2001) 1.28
Signature tau neuropathology in gray and white matter of corticobasal degeneration. Am J Pathol (2002) 1.28
Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am J Pathol (2007) 1.26
Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome. J Biol Chem (2008) 1.22
Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J Biol Chem (2009) 1.21
Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathol (2012) 1.21
The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. Pharmacol Res (2010) 1.20
Axonal stress kinase activation and tau misbehavior induced by kinesin-1 transport defects. J Neurosci (2009) 1.16
SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans. Hum Mol Genet (2009) 1.16
Knock-out and transgenic mouse models of tauopathies. Neurobiol Aging (2007) 1.14
Pin1 in Alzheimer's disease: multiple substrates, one regulatory mechanism? Biochim Biophys Acta (2007) 1.13
Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics (2008) 1.13
Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam. Am J Pathol (2002) 1.11
Tau and neurodegenerative disease: the story so far. Nat Rev Neurol (2015) 1.10
Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies. Proc Natl Acad Sci U S A (2005) 1.10
Obesity, leptin, and Alzheimer's disease. Ann N Y Acad Sci (2011) 1.09
Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol (2009) 1.08
(+)-Discodermolide: Total Synthesis, Construction of Novel Analogues, and Biological Evaluation. Tetrahedron (2007) 1.07
Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry (2012) 1.07
Missense mutation in the tubulin-specific chaperone E (Tbce) gene in the mouse mutant progressive motor neuronopathy, a model of human motoneuron disease. J Cell Biol (2002) 1.05
Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am J Pathol (2005) 1.05
The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Res Rev (2013) 1.05
Tau and tauopathies. Prog Mol Biol Transl Sci (2012) 1.04
Biochemical analysis of tau proteins in argyrophilic grain disease, Alzheimer's disease, and Pick's disease : a comparative study. Am J Pathol (2002) 1.04
Are tau aggregates toxic or protective in tauopathies? Front Neurol (2013) 1.03
E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J Biol Chem (2011) 1.03
Expression of the small heat-shock protein alphaB-crystallin in tauopathies with glial pathology. Am J Pathol (2004) 1.03
Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol (2012) 1.03
Accumulation of vesicle-associated human tau in distal dendrites drives degeneration and tau secretion in an in situ cellular tauopathy model. Int J Alzheimers Dis (2012) 1.02
Soluble forms of tau are toxic in Alzheimer's disease. Transl Neurosci (2012) 1.02
Is tau ready for admission to the prion club? Prion (2012) 1.01
Lessons from tau-deficient mice. Int J Alzheimers Dis (2012) 1.01
What Renders TAU Toxic. Front Neurol (2013) 1.00
Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol (2003) 1.00
Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging. J Neurosci (2014) 0.97
P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS One (2011) 0.97
Dysregulation of protein phosphorylation/dephosphorylation in Alzheimer's disease: a therapeutic target. J Biomed Biotechnol (2006) 0.96
Erythropoietin plus insulin-like growth factor-I protects against neuronal damage in a murine model of human immunodeficiency virus-associated neurocognitive disorders. Ann Neurol (2010) 0.96
Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease. Bioorg Med Chem (2013) 0.94
NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy. Mol Psychiatry (2013) 0.94
Modes of Aβ toxicity in Alzheimer's disease. Cell Mol Life Sci (2011) 0.94
Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease. Neurodegener Dis (2009) 0.94
Staging of neurofibrillary degeneration caused by human tau overexpression in a unique cellular model of human tauopathy. Am J Pathol (2001) 0.94
Proteasome inhibition drives HDAC6-dependent recruitment of tau to aggresomes. J Mol Neurosci (2011) 0.93
Cytosolic proteins lose solubility as amyloid deposits in a transgenic mouse model of Alzheimer-type amyloidosis. Hum Mol Genet (2013) 0.92
HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila. Proc Natl Acad Sci U S A (2013) 0.92
Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease. Am J Pathol (2008) 0.92
Tau as a therapeutic target in neurodegenerative disease. Pharmacol Ther (2012) 0.92
Vaccination as a therapeutic approach to Alzheimer's disease. Mt Sinai J Med (2010) 0.92
The role of tau in Alzheimer's disease and related disorders. CNS Neurosci Ther (2010) 0.91
Glial fibrillary tangles and JAK/STAT-mediated glial and neuronal cell death in a Drosophila model of glial tauopathy. J Neurosci (2010) 0.90
Reduced axonal transport and increased excitotoxic retinal ganglion cell degeneration in mice transgenic for human mutant P301S tau. PLoS One (2012) 0.89
MSUT2 is a determinant of susceptibility to tau neurotoxicity. Hum Mol Genet (2011) 0.88
Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans (2012) 0.88
Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. Curr Pharm Des (2012) 0.88
Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A. Neurobiol Aging (2011) 0.87
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Linkage of early-onset familial breast cancer to chromosome 17q21. Science (1990) 16.21
TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature (2001) 11.84
Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol (2001) 9.96
Neurodegenerative tauopathies. Annu Rev Neurosci (2001) 9.53
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol (2003) 9.10
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A (2006) 6.33
ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron (1997) 6.16
Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol (1997) 6.12
An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron (1995) 6.03
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science (2000) 5.62
A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science (1991) 5.60
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science (2001) 5.40
Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron (1996) 5.30
Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron (1996) 5.14
Use of oral corticosteroids and risk of fractures. J Bone Miner Res (2000) 4.75
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron (1997) 4.49
A three-hybrid system to detect RNA-protein interactions in vivo. Proc Natl Acad Sci U S A (1996) 4.44
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol (1996) 4.10
Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science (1998) 4.07
A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem (2000) 3.97
Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci (2000) 3.90
Closing in on a breast cancer gene on chromosome 17q. Am J Hum Genet (1992) 3.89
Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes (2001) 3.83
Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron (1997) 3.73
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science (1996) 3.53
Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron (1993) 3.45
Isolation and chromosomal assignment of 100 highly informative human simple sequence repeat polymorphisms. Genomics (1992) 3.42
A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun (1985) 3.40
Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc Natl Acad Sci U S A (1994) 3.36
Epitopes that span the tau molecule are shared with paired helical filaments. Neuron (1988) 3.28
Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res (1994) 3.26
Nonsyndromic deafness DFNA1 associated with mutation of a human homolog of the Drosophila gene diaphanous. Science (1997) 3.21
A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal (1996) 3.18
Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol (1997) 3.03
Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med (1996) 2.95
Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res (1996) 2.91
Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci (2001) 2.89
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell (1992) 2.80
Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med (1999) 2.74
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
The human mid-size neurofilament subunit: a repeated protein sequence and the relationship of its gene to the intermediate filament gene family. EMBO J (1987) 2.72
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67
Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science (1994) 2.65
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology (2006) 2.65
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology (2011) 2.61
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Sublingual capnometry: a new noninvasive measurement for diagnosis and quantitation of severity of circulatory shock. Crit Care Med (1999) 2.54
Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res (2001) 2.50
Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons. J Neurosci (1992) 2.50
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol (1998) 2.47
Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci (1998) 2.43
Mutation in transcription factor POU4F3 associated with inherited progressive hearing loss in humans. Science (1998) 2.42
Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. J Biol Chem (2000) 2.42
Synucleinopathies: clinical and pathological implications. Arch Neurol (2001) 2.36
Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest (1992) 2.30
A novel extracellular cyclic lipopeptide which promotes flagellum-dependent and -independent spreading growth of Serratia marcescens. J Bacteriol (1992) 2.30
Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci U S A (1999) 2.30
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology (2000) 2.27
Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci U S A (1999) 2.26
Recalcitrant chronic adhesive capsulitis of the shoulder. Role of contracture of the coracohumeral ligament and rotator interval in pathogenesis and treatment. J Bone Joint Surg Am (1989) 2.24
Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology (2004) 2.23
Association of Trp64Arg mutation of the beta3-adrenergic-receptor with NIDDM and body weight gain. Diabetologia (1996) 2.22
Tears of the rotator cuff of the shoulder associated with pathological changes in the acromion. A study in cadavera. J Bone Joint Surg Am (1988) 2.21
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci (2001) 2.16
Broadband observations of the naked-eye gamma-ray burst GRB 080319B. Nature (2008) 2.16
Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med (1997) 2.15
Two-stage expression of neurofilament polypeptides during rat neurogenesis with early establishment of adult phosphorylation patterns. J Neurosci (1987) 2.15
Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc Natl Acad Sci U S A (1996) 2.14